AbbVie Inc. Stock
€195.80
Your prediction
Description AbbVie
AbbVie (ABBV) is a publicly listed pharmaceuticals company headquartered in North Chicago, Illinois, United States. It was established in 2013 as a spinoff from Abbott Laboratories, and currently operates in more than 175 countries worldwide. The company has over 47,000 employees and specializes in research, development, and the commercialization of advanced therapies for a variety of diseases, including immunology, oncology, neuroscience, and virology.
ABBV's flagship product is Humira, which is used to treat a range of autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is one of the best-selling prescription drugs globally, generating over $19 billion in 2019.
In addition to Humira, AbbVie also has several other leading drugs in its product portfolio, including Imbruvica, which is used to treat B-cell malignancies like leukemia and lymphoma, and Skyrizi, which is used to treat psoriasis.
ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV, and it is a constituent of the S 500 index. As of 2021, AbbVie has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of AbbVie
AbbVie's most important competitors in the pharmaceutical industry are:
1. Johnson Johnson (Symbol: JNJ)
2. Pfizer Inc. (Symbol: PFE)
3. Merck Co., Inc. (Symbol: MRK)
4. Roche Holding AG (Symbol: RHHBY)
5. Sanofi S.A. (Symbol: SNY)
These companies are all large multinational pharmaceutical companies with strong development pipelines, extensive product portfolios, and substantial global reach. They compete with AbbVie in areas such as immunology, oncology, virology, and neuroscience. In addition, they all have a significant presence in emerging markets, where they are competing to capture market share and grow their businesses. Competition in the pharmaceutical industry is intense, and these companies are continually striving to develop new and innovative drugs to stay ahead of their rivals.
Suppliers of AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients. The company has a number of important suppliers that help it manufacture the drugs it develops, and ensure the quality and safety of its products. Here are some of the most important suppliers of AbbVie:
1. Raw materials suppliers: AbbVie sources raw materials such as chemical compounds, active pharmaceutical ingredients (APIs), excipients, and packaging materials from a wide range of suppliers around the world. These include large chemical and pharmaceutical companies, as well as smaller suppliers specialized in specific raw materials.
2. Contract manufacturers: AbbVie works with a number of contract manufacturers to produce its drugs on a large scale. These manufacturers operate facilities in the United States, Europe, and Asia, and are selected based on their expertise in specific manufacturing processes and their ability to meet AbbVie's quality standards.
3. Equipment and technology suppliers: AbbVie also relies on a variety of suppliers for equipment and technology used in its manufacturing processes. These include providers of specialized laboratory equipment, automated drug manufacturing systems, and software systems for tracking and documenting production processes.
4. Service providers: AbbVie works with a range of service providers to ensure the quality and safety of its products. These include companies that provide testing and analysis of raw materials and finished products, logistics and transportation services, and certification and compliance services.
Overall, AbbVie's suppliers play a critical role in the company's ability to develop and deliver innovative medicines to patients around the world. The company has established strong relationships with these suppliers to ensure the reliability and consistency of its supply chain, and continues to seek out new partners to support its ongoing research and development efforts.
Financial data and news for AbbVie
sharewise wants to provide you with the best news and tools for AbbVie, so we directly link to the best financial data sources.
Financials
News
Healthcare Rotation Underway: 3 Stocks Leading the Charge
Is the artificial intelligence revolution hitting its first roadblock? For the first time since the AI boom began in 2023, the industry is starting to feel the weight of expectations, and many of
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
AbbVie Inc. (NYSE: ABBV) delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an increase in its forward guidance. The results clear the way for ABBV stock
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
For many investors, getting involved with pharmaceutical stocks involves finding inexpensive stocks, often penny stocks, in hopes of investing in a breakthrough treatment for cancer, Alzheimer’s
3 Exceptional Stocks to Build Long-Term Wealth
With many stocks looking overvalued, many investors may be tempted to sell. However, there are several factors to consider before taking profits:
- Time horizon – when an investor will need the
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net
Could Buying AbbVie Today Set You Up for Life?
One effective way to earn solid, long-term returns is to invest in dividend-paying stocks since reinvesting the payout can help boost stock performance. However, they aren't all created equal, and
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years
Want some quality income-generating investments you can put in your portfolio for the long term, and not worry about? The stocks listed below check off those boxes and can make for ideal investments
AbbVie Stock Falls 4% -- What Investors Need to Know
Earnings season creates short-term winners and losers, companies whose shares rise or fall after they announce their quarterly updates. The good news is that among these short-term losers, there are
5 Top Stocks to Buy in November
As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all
Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now
A $5,000 investment may not seem like a large amount of money to invest in the stock market. But you can make the most of it by investing for the long haul, and picking modestly valued growth
3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November
The stock market is near all-time highs as Wall Street chugs through earnings season and eyes the end of the year just around the corner.
But not all stocks are hitting new heights. Some prominent
2 Magnificent Dividend Stocks to Buy and Hold Forever
Dividends are one of investors' most powerful tools for earning strong returns over the long run. Buying shares of strong dividend-paying companies and reinvesting the payout allows compounding to
Why AbbVie Stock Flopped on Friday
AbbVie's (NYSE: ABBV) products are regularly used to help heal the sick, but the company's stock wasn't healthy for portfolios on Friday. The company published its latest quarterly earnings release
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth
Image source: Getty Images
LOS ANGELES CAPITAL MANAGEMENT LLC increased its position in AbbVie by 304,281 shares during Q3 2025, an estimated $61.96 million trade based on the average price for Q3
AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector
Explore the exciting world of AbbVie (NYSE: ABBV) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends
2 Dividend Stocks to Double Up on Right Now
Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining
Carolina Wealth Trims It's AbbVie Stake to Nearly Nothing
Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79
Why AbbVie Stock Soared in September
Any pharmaceutical company as large and sprawling as AbbVie (NYSE: ABBV) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications
3 Dividend Stocks to Double Up On Right Now
If x is good, isn't 2x even better? Usually. Granted, there can be too much of a good thing. For example, you might regret eating two giant helpings of ice cream rather than one. However, in many
St Louis Financial Loads Up on AbbVie (ABBV) With 14,600 Shares Buy
St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (NYSE:ABBV), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.
According to a Securities and
Why AbbVie Stock Cruised to an Almost 6% Gain Today
The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (NYSE: ABBV) stock on Wednesday. The pharmaceutical company's shares rose by
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Stocks in the S&P 500 (SNPINDEX: ^GSPC) offer a miserly yield of 1.2% (on average) today. You can do way better than that and still invest in very attractive businesses. To prove that out, just look
Where Will AbbVie Be in 5 Years?
AbbVie (NYSE: ABBV) ranks as the third-largest pharmaceutical company in the world, with a market capitalization hovering around $390 billion. It markets around a dozen blockbuster drugs, plus many
1 Top Dividend Stock to Buy and Hold Forever
Strong dividend payers can be a stabilizing force in a well-diversified portfolio. That's because corporations that can consistently pay and raise their payouts over a long period are often
What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
It isn't easy to find a pharmaceutical company that has a strong product lineup and a robust pipeline, but also cranks out a generous dividend every quarter. I've been an AbbVie (NYSE: ABBV) bull


